Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Riccardo Bomben et al.|The Lancet Haematology|2025Cited by 6
Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center ExperienceMarcello Riva, Fausto Adami, Tamara Berno et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trialRiccardo Moia, Monica Balzarotti, Mohammad Almasri et al.|Blood Advances|2026Cited by 0